Ensysce Biosciences Secures New U.S. Patent for MPAR® Overdose Protection Technology, Extending Coverage Through 2042
I'm PortAI, I can summarize articles.
Ensysce Biosciences Inc. has received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering its MPAR® (Multi-Pill Abuse Resistance) technology. The patent extends protection through 2042 and includes composition-of-matter and method-of-use claims. MPAR® technology is designed to provide overdose protection by moderating opioid release when taken in excess. This news was originally published by Ensysce Biosciences Inc. via ACCESS Newswire on December 02, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments